UCB, Teva, Novartis, Pfizer and TransCelerate Biopharma win industry recognition at the eyeforpharma Philadelphia Awards 2016

eyeforpharma 2 - 3 May 2016, Philadelphia, USA.
The 2016 eyeforpharma Philadelphia Awards saw 22 finalists, with representation from every top 20 pharma, showcase the breadth of innovation within the industry. Submissions displayed cutting-edge application of new strategies for old problems.

Teva won the Most Valuable HCP or Healthcare Initiative with their foray into Artificial Intelligence. Teva presented "ASK Claire", an Intelligent Virtual Health Assistant that engages Multiple sclerosis (MS) patients on the web and in an app.

UCB picked up the Most Valuable Patient Initiative or Service Award with their Report Cards submission. The team presented an intriguing approach to create new incentives for decision makers to prioritise innovative therapies for Epilepsy Patients, by creating transparency into current care outcomes.

Individual leaders were also recognized for their refusal to accept the status quo, showing the way for the industry to progress. Chrisi Shaw, the, U.S. Country Head and President of Novartis picked up the Lifetime Achievement Award for her leadership on gender equality and contributions to patient-centricity throughout the pharma lifecycle.

Pfizer's Dennis Freire was awarded for his contributions towards patient-centric clinical trials with the Customer Innovator Award. Through a collaboration with ICON Firecrest collaboration, Freire oversaw a radical re-think of the onerous procedures facing patient registrants for clinical trials.

The groundbreaking consortium of top 20 pharma TransCelerate was also recognized with the Most Valuable Pharma Collaboration award for the work they've achieved in unlocking innovation that benefits everyone in pharma. Through shared research partnerships and close regulatory coordination, they are redefining the boundaries of what is possible in cross-industry collaboration on issues of shared commercial, and patient-centric interest.

The awards reflect eyeforpharma's mission to evangelize the need for pharma to change its focus from selling products, to seeing the powerful opportunity that pharma has to impact and improve the lives of patients. The winning projects were selected from hundreds of initiatives submitted from teams across the global, and determined by a judging panel of senior industry experts, and patient advocates.

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

More stroke patients may receive crucial treatment…

More patients could be eligible for critical treatments to remove or dissolve blood clots that cause strokes, according to a new treatment guideline issued by the America...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Cells of 3 advanced cancers die with drug-like com…

Researchers at Southern Methodist University have discovered three drug-like compounds that successfully reverse chemotherapy failure in three of the most commonly aggres...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]